MedTrace Logo

Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Non-Erosive Gastroesophageal Reflux Disease (NERD)

NCT06121830 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 324

Last updated 2023-11-08

No results posted yet for this study

Summary

This study is designed to determine the efficacy and safety of DWP14012 compared to a placebo following a once-daily oral dose of DWP14012 at 20 mg, 40 mg, or placebo for 4 weeks in patients with NERD.

Conditions

  • Non-erosive Reflux Disease
  • Non-Erosive Gastro-Esophageal Reflux Disease
  • Non-Erosive Esophageal Reflux Disease

Interventions

DRUG

DWP14012 20mg

DWP14012 20mg, tablet, orally, once daily for up to 4 weeks

DRUG

DWP14012 40mg

DWP14012 40mg, tablet, orally, once daily for up to 4 weeks

DRUG

Placebo

Placebo, tablet, orally, once daily for up to 4 weeks

Sponsors & Collaborators

  • Daewoong Pharmaceutical Co. LTD.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-31
Primary Completion
2025-01-31
Completion
2025-03-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06121830 on ClinicalTrials.gov